Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.5 mg to 10 mg) of BI 1356 BS as Formulation for Intravenous Administration in Healthy Male Volunteers. A Randomised, Single-blind, Placebo-controlled Trial, Including a Crossover Intra-subject Bioavailability Comparison of 5 mg BI 1356 BS iv Solution and 10 mg BI 1356 BS as Tablet.

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.5 mg to 10 mg) of BI 1356 BS as Formulation for Intravenous Administration in Healthy Male Volunteers. A Randomised, Single-blind, Placebo-controlled Trial, Including a Crossover Intra-subject Bioavailability Comparison of 5 mg BI 1356 BS iv Solution and 10 mg BI 1356 BS as Tablet.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linagliptin (Primary) ; Linagliptin (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 16 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top